Clinical trial
Study of Eteplirsen in DMD Patients
NCT02255552 · Sarepta Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT02255552 |
|---|---|
| Title | Study of Eteplirsen in DMD Patients |
| Official title | An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy |
| Acronym | PROMOVI |
| Lead sponsor | Sarepta Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Duchenne Muscular Dystrophy (DMD) |
| Intervention type | Drug |
| Interventions | eteplirsen |
| Enrollment | 109 |
| Start date | Nov 17, 2014 |
| Primary completion | Jun 14, 2019 |
| Completion | Jun 14, 2019 |
| First posted | Oct 2, 2014 |
| Last update posted | Jan 25, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: